Changes in the Turnover of the Cellular Proteome during Metabolic Reprogramming: A Role for mtROS in Proteostasis by García-Aguilar, Ana et al.
Changes in the Turnover of the Cellular Proteome during Metabolic
Reprogramming: A Role for mtROS in Proteostasis
Ana García-Aguilar,† Inmaculada Martínez-Reyes,† and Jose ́ M. Cuezva*
Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Centro de Investigacioń
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ABSTRACT: The role played by protein turnover in metabolic reprogramming
is unknown. Herein, using a SILAC approach, we have studied the changes in the
half-life of 266 proteins of energy metabolism and of translation during the
metabolic switch induced by the prolyl hydroxylases inhibitor dimethyloxalyl-
glycine (DMOG). DMOG induces HIF-1α expression and triggers the activation
of glycolysis and the concurrent inhibition of mitochondrial respiration in colon
cancer cells. Changes in the activity of energy provision pathways correlated with
increased turnover rates of glycolytic enzymes and the stabilization of
mitochondrial proteins. Moreover, reprogramming also stabilized the proteins
of translation. The partial DMOG-mediated arrest of the synthesis of
mitochondrial and translation proteins results from the inhibition of the mTORC1/p70SK/S6 signaling pathway. In contrast,
DMOG stimulated the synthesis of glycolytic enzymes, emphasizing the opposite and differential regulation of the two pathways
of energy provision. Addition of MitoQ, a mitochondrial reactive oxygen species (mtROS) scavenger, stabilized the turnover of
cellular proteins similarly as when protein degradation is inhibited with leupeptin, a serine-protease inhibitor. Overall, the results
show that the higher the activity of a pathway the lower is the half-life of the proteins involved and suggest a role for mtROS in
cellular proteostasis. Data are available via ProteomeXchange with identifier PXD013482.
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■ INTRODUCTION
Tumor cells reprogram metabolism to cope with the increased
metabolic demand imposed by uncontrolled proliferation and
for adaptation to the microenvironment.1−3 Under hypoxia,
cancer cells activate the hypoxia-inducible transcription factor-
1α (HIF-1α), a master regulator of the hypoxic response,
which mediates the regulation of the expression of genes
involved in angiogenesis, erythropoiesis, metabolism, cell
survival and proliferation.4−7 The activation of HIF-1α triggers
the specific translation of selective mRNAs encoding proteins
of metabolism involved in promoting a shift from oxidative
phosphorylation (OXPHOS) to glycolysis to maintain energy
production.8 Under normal oxygen tension, HIF-1α is
hydroxylated by a group of enzymes called prolyl-4-
hydroxylases (PHD).9 Hydroxylation of HIF-1α allows its
recognition by a protein-ubiquitin ligase complex containing
the tumor suppressor von Hippel-Lindau E3, promoting its
ubiquitination and proteasomal degradation.10,11 In contrast,
under hypoxic conditions, the activity of PHDs is inhibited
resulting in HIF-1α stabilization.10 Dimethyloxaloylglycine
(DMOG) is a competitive inhibitor of the prolyl and
asparaginyl hydroxylases that promotes HIF-1α stabilization
and has been extensively used to study hypoxia driven effects.
In fact, DMOG reprograms energy metabolism by repressing
mitochondrial respiration while activating glycolysis in
cardiomyocytes12 and in cancer cell lines.13,14
Proteins are in dynamic equilibrium in vivo as they are
continuously synthesized and degraded during the lifetime of
the organism.15 The constant recycling (turnover) of proteins
is an energy consuming process that offers a safeguard strategy
against protein damage and for rapid cellular adaptation to
changes in the environment.16 The mammalian target of
rapamycin complex 1 (mTORC1) signaling pathway is key in
coordinating anabolic and catabolic processes to maintain
homeostasis including the regulation of protein synthesis and
degradation.17−19 Proper proteome dynamics is necessary for
normal development and health maintenance,20,21 being
influenced by a large number of cell-type regulated processes
and by the biochemical properties of the molecules itself.22
Conversely, dysregulation of protein turnover has been
implicated in aging and in the pathogenic accumulation of
protein aggregates in neurological diseases.23,24 Because
proteins can turnover rapidly, even when they are in steady
state, we have used metabolic labels that are incorporated or
lost from the proteins to measure their turnover rates.25 In this
study, we have used DMOG as a tool to investigate the
potential role of protein turnover in metabolic reprogramming.
We demonstrate that the turnover rate of glycolytic enzymes is
significantly accelerated during metabolic rewiring to an
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enhanced glycolysis by DMOG treatment. In contrast, the
turnover of the mitochondrial, ribosomal, and other trans-
lation-related proteins is significantly slowed-down concur-
rently with the inhibition of the mTORC1 pathway. In other
words, the turnover of enzymes of energy metabolism inversely
correlates with the flux of matter and energy through the
metabolic pathway in which the proteins participate.
Incubation of the cells with a mitochondrial ROS (mtROS)
scavenger or the inhibition of serine proteases significantly
decelerate the overall turnover of cellular proteins, suggesting
the implication of oxidative damage of proteins as a factor
involved in the regulation of protein turnover during metabolic
reprogramming.
■ MATERIALS AND METHODS
Cellular Treatments
Human colorectal carcinoma HCT116 cells were grown at 37
°C and 5% CO2 in McCoy’s 5A media supplemented with 10%
fetal bovine serum. Cells were left untreated (CRL), treated
with 1 mM dimethyloxaloylglycine (DMOG) (Enzo Life
Science) for 24−48 h, 20 nM MitoQ for 48 h or 200 μM
leupeptin (Sigma) for 24 h. After cell recovery and lysis (see
protein extraction), protein concentration was determined with
the Bradford reagent.
Determination of Glycolysis and Cellular Respiration
The initial rate of lactate accumulation in the culture media
was used as an index of glycolysis.26 Oxygen consumption rates
(OCR) were determined in a XF24 Extracellular Flux Analyzer
(Seahorse Bioscience). Cells were seeded in the microplates
for 24h and the OCR determined after the addition of 6 μM
oligomycin, 0.75 mM 2,4-dinitrophenol (DNP), 1 μM
rotenone plus 1 μM antimycin.27
Western Blots
Cellular extracts were fractionated by SDS/PAGE and
transferred on to PVDF membranes. The primary monoclonal
antibodies used in this study were: anti-Hsp60 (clone 17/9−
15 G1, 1:5000), anti-β-F1-ATPase (clone 11/21−7 A8,
1:1000) and anti-GAPDH (1:20 000).28 Other antibodies
used were anti-HIF-1α (1:150) from Santa Cruz Biotechnol-
ogy, anti-CDK1 (1:1000), anti-p-CDK1 (1:1000), anti-eIF3A
(1:1000), anti-eIF4E (1:1000), anti-p-mTOR (1:500), anti-
mTOR (1:1000), anti-p-P70S6K (1:1000), anti-P70S6K
(1:1000), anti-S6 (1:1000), anti-p-S6 (1:1000), anti-p-4EBP1
(1:1000) and anti-4EBP1 (1:1000) from Cell signaling, anti-
eIF3D (1:1000) from Acris, anti-ENO1 (1:1000) from
Abyntek Biopharma and anti-β-actin (1:10 000) and eIF3E
(1:1000) from Sigma. Anti-P0 (1:1000) and anti-P1/P2
(1:1000) antibodies were kindly provided by Dr. J.P.G.
Ballesta (CBMSO). Peroxidase-conjugated antimouse or
antirabbit IgGs (Nordic Immunology; 1:3000) were used as
secondary antibodies. The blots were revealed using a
chemiluminescence detection method (ECL, Invitrogen).
Quantification of the immunoreactive bands (arbitrary units)
was accomplished using a Kodak DC120 Zoom digital camera
and the Kodak 1D Image Analysis Software for Windows.
Determination of Cell Proliferation
The incorporation of 5-ethynyl-20deoxy-uridine (EdU) into
cellular DNA was determined using the Click-iT EdU Flow
Cytometry Assay Kit (Molecular Probes). Cells were analyzed
in a FACScan. For each analysis 10 000 events were recorded.
Determination of the Rates of β-F1-ATPase and GAPDH
Synthesis and Turnover Using 35S-Met
Cells were incubated 20 min in cysteine-methionine-free
medium. Metabolic labeling was performed by adding an
aliquot of medium supplemented with 0.65 mCi of 35S-Met/
mL. For the determination of the rates of protein synthesis
incorporation of the tracer was allowed during 20 min in the
absence or presence of DMOG.28 For pulse-chase experiments,
incorporation of the label was for 1 h, and after washing the
radioactive medium cells were recovered at the indicated time
points and resuspended in RIPA buffer (0.5 M NaCl, 2%
Triton X-100, 0.1 M Tris-HCl pH 8.0, 0.2% SDS, 1% Na-
DOC) supplemented with protease inhibitor cocktail (Roche)
and freeze−thawed three times. The radioactivity incorporated
into TCA precipitable protein was also determined.
Immunoprecipitations were carried out from 100 μg protein
of cellular extracts using G-sepharose precoated with 6 μg of
the IgGs of the corresponding monoclonal antibodies.
Stable Isotope Labeling with Amino Acids in Cell Culture
(SILAC)
HCT116 cells were grown in McCoy’s 5A SILAC media
containing L-glutamine deficient in both L-arginine and L-lysine
(Thermo Fisher) and supplemented with 10% dialyzed fetal
bovine serum (dFBS) (Thermo Fisher). L-arginine and L-lysine
were added in either light (Arg0, Sigma, A5006; Lys0, Sigma,
L5501) or heavy form (Arg10, Thermo Fisher, 89990; Lys8,
Thermo Fisher, 88209). Trypsin-EDTA was avoided at all
stages of passaging. Proteins were tested for higher than 98%
incorporation of the heavy labeled amino acids after nine
passages by mass spectrometry.
To assess the effect of DMOG on protein turnover, three
p60 plates of treated or untreated cells were mixed at the
following time points: 0, 6, 12, 24, and 48 h and further
processed for protein extraction and identification. To assess
the effect of MitoQ, MitoQ+DMOG and leupeptin on protein
turnover, cells treated as indicated were sampled at 0, 6, 12,
and 24 h.
Protein Extraction and Digestion for SILAC
For protein extraction 20 × 106 cells/mL was lysed with 50
mM Tris-HCl pH 8.0 containing 150 mM NaCl, 0.02%
sodium azide, 0.1% SDS, 1% NP-40, 0.5% sodium deoxy-
cholate, the complete protease inhibitor cocktail EDTA-free
(Roche) and the Phosphatase Inhibitor Cocktail (Sigma-
Aldrich) for 15 min on ice. Extracts were centrifuged at
11 000g for 15 min at 4 °C. Protein extracts (30 μg), were
suspended in 100 μL of sample buffer, and then applied onto
1.2 cm wide wells of a conventional SDS-PAGE gel (0.75 mm-
thick, 4% stacking, and 10% resolving). The run was stopped as
soon as the front entered 3 mm into the resolving gel to
concentrate the proteome. The band was visualized by
Coomassie staining (GelCode Blue Stain Reagent_Thermo-
Fisher), excised, cut into cubes (2 × 2 mm), and placed in 0.5
mL microcentrifuge tubes.29 The gel pieces were destained in
acetonitrile:water (1:1), were reduced with 10 mM DTT for 1
h at 56 °C and the thiol groups were alkylated with 50 mM
iodoacetamide for 1 h at room temperature in the dark,
followed by in situ digestion with sequencing grade trypsin
(Promega, Madison, WI).30 Gel pieces were shrunk using
acetonitrile and dried out in a speedvac. The dried gel pieces
were reswollen in 50 mM ammonium bicarbonate pH 8.8 with
60 ng/μL trypsin at 5:1 protein:trypsin (w/w) ratio. The tubes
were kept in ice for 2 h and incubated at 37 °C for 12 h.
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Digestion was stopped by the addition of 1% trifluoroacetic
acid. Supernatants were dried-down and then desalted onto
OMIX Pipette tips C18 (Agilent Technologies) until the mass
spectrometric analysis.
Reverse Phase-Liquid Chromatography RP-LC−MS/MS
Analysis (Dynamic Exclusion Mode)
The desalted protein digest was dried, resuspended in 10 μL of
0.1% formic acid and analyzed by RP-LC−MS/MS (reverse
phase liquid chromatography tandem-mass spectrometry) in
an Easy-nLC II system coupled to an ion trap LTQ-Orbitrap-
Velos-Pro hybrid mass spectrometer (Thermo Scientific). The
peptides were concentrated (online) by reverse phase
chromatography using a 0.1 mm × 20 mm C18 RP precolumn
(Thermo Scientific), and then separated using a 0.075 mm ×
250 mm C18 RP column (Thermo Scientific) operating at 0.3
μL/min. Peptides were eluted using a 220 min dual gradient:
from 5 to 25% solvent B in 135 min and from 25 to 40%
solvent B in 45 min. The gradient was followed by 40 to 100%
solvent B in 2 min, 18 min in 100% solvent B, from 100 to 5%
solvent B in 2 and 18 min in 5% solvent B (Solvent A: 0,1%
formic acid in water, solvent B: 0,1% formic acid, 80%
acetonitrile in water). ESI ionization was done using a
Nanobore emitter Stainless Steel ID 30 μm (Proxeon)
interface.31 The Orbitrap resolution was set at 30.000. Peptides
were detected in survey scans from 400 to 1600 amu (1
μscan), charge state rejection +1, collision-induced dissociation
(CID) fragmentation mode in linear ion trap (LIT) followed
by 20 data dependent MS/MS scans (Top 20), using an
isolation width of 2 u (in mass-to-charge ratio units),
normalized collision energy of 35%, and dynamic exclusion
applied during 60 s periods.
Protein Identification
Protein identification from raw data was carried out using
PEAKS Studio 8.5 software (Bioinformatics Solutions
Inc.).32−34 Database search was performed against uniprot-
Homo sapiens.fasta 12/03/2018 containing 71790 sequences
(decoy-fusion database). The following constraints were used
for the searches: tryptic cleavage after Arg and Lys, up to two
missed cleavage sites, and tolerances of 20 ppm for precursor
ions and 0.6 Da for MS/MS fragment ions with a filter charge
between 2 and 4 and the searches were performed allowing
optional Met oxidation, Cys carbamidomethylation and 13C(6)
15N(2) K, 13C(6) 15N(4) R Silac Label. False discovery rates
(FDR) for peptide spectrum matches (PSM) was limited to
0.01. Only those proteins with at least two distinct peptides
being discovered from LC/MS/MS analyses were considered
reliably identified.
Quantification of Protein Turnover
Quantitation of SILAC labeled peptides was performed with
PEAKS Studio 8.5 search engine (Bioinformatics Solutions
Inc.),32−34 selected “Precursor Ion Quantification SILAC”
under the “Quantifications” options. We use NO normalization
mode. Charge between 2 and 4. The −10LogP, Quality, and
Average Area were used for Feature vector filter and
Significance (Peaks Q method) for Protein filter. For the
protein quantification we consider protein groups for peptide
uniqueness, use only unique peptides. The H/L ratio for each
protein was determined by PEAKS Studio 8.5 as the median of
all of the peptides assigned to the protein.35,36 We used the
time-dependent decay of labeled peptides (ratio H/H+L) to
measure the t1/2 for each protein following the detailed
protocol in the literature.37 In cells treated or not with DMOG
the time points sampled after addition of light medium were 0,
6, 12, 24, and 48 h (experiment 1, see Supplemental Tables
S1−S3). In cells treated with leupeptin or MitoQ (experiment
2, see Supplemental Tables S4−S7) or MitoQ plus DMOG
(experiment 3, see Supplemental Tables S4−S7) the time
points sampled after the addition of the light medium were 0,
6, 12, and 24 h.
Bioinformatics Analysis
We used the GeneCodis web tool38−40 to analyze the pathways
more affected by DMOG treatment.
Preparation and LC-ESI-MS/MS Identification of Ribosomal
Proteins
Cells at 80% confluence were harvested and incubated in a
buffer containing 250 mM sucrose, 250 mM KCl, 5 mM
MgCl2, 50 mM Tris·Cl, pH 7.4 and NP-40 0.7% (v/v). The
nuclear fraction was removed and the cytoplasmic fraction was
centrifuged at 12,500g to remove the mitochondrial fraction.
The concentration of the postmitochondrial fraction was then
adjusted to 0.5 M KCl to disrupt most interactions between
ribosomes and other proteins of other cell compartments.
Finally, ribosomes were purified through a 0.5 M KCl sucrose
cushion by ultracentrifugation. The purification of the
ribosomal fraction was validated by one-dimensional SDS
polyacrylamide gel electrophoresis (SDS-PAGE). Protein
extracts were precipitated in methanol-chloroform and
dissolved in 8 M urea, 25 mM ammonium bicarbonate,
reduced and alkylated with iodoacetamide, according to a
method previously described.41 Urea concentration was
reduced to 2 M with 25 mM ammonium bicarbonate (final
volume 40 μL) and the samples digested overnight at 37 °C
with recombinant MS-grade trypsin (Sigma-Aldrich), with a
ratio of 25:1. After digestion, samples were desalted using
ZipTip (Merck) as described. Nano LC-ESI-MS/MS analysis
of the trypsin digested ribosomal fraction was performed using
an Eksigent 1D-nanoHPLC coupled to a 5600TripleTOF
QTOF mass spectrometer (ABSciex, Framinghan, MA, USA).
The analytical column used was a silica-based reversed phase
column Eksigent chromXP 75 μm × 15 cm, 3 μm particle size
and 120 Å pore size. The trap column was a chromXP, 3 μm
particle diameter, 120 Å pore size, switched online with the
analytical column. The loading pump delivered a solution of
0.1% trifluoroacetic acid in 98% water/2% acetonitrile
(LabScan, Gliwice, Poland) at 30 μL/min. The nanopump
operated under gradient elution conditions at a flow-rate of
300 nL/min, using 0.1% formic acid (Fluka, Buchs, Switzer-
land) in water as mobile phase A, and 0.1% formic acid in 80%
acetonitrile/20% water as mobile phase B. Gradient elution
was isocratic conditions of 96% A: 4% B for 5 min, a linear
increase to 40% B in 60 min, followed by a washing step of 7
min of 95% B. Injection volume was 5 μL. The LC system was
coupled via a nanospray source to the mass spectrometer. Full
scan (m/z 350−1250) MS spectra followed by tandem MS
CID spectra of the 25 most abundant ions were obtained in
data-dependent acquisition mode. MS and MS/MS data were
used to search against the UniprotKb database using a Mascot
v.2.3.02 (Matrix Science, London, UK) containing the
sequences of interest. Peptides with scores above threshold
were selected, and based on these individual scores protein
identifications were assigned. Search parameters were
carbamidomethyl cysteine as fixed modification and oxidized
proline and methionine as variable ones. Peptide mass
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tolerance was set at 25 ppm and 0.6 Da for MS and MS/MS
spectra, respectively, and 1 missed cleavage was allowed.
RNA Extraction and Quantification of mRNA Expression
RNA was purified from untreated and 1 mM DMOG-treated
HCT116 cells with Trizol Reagent (Thermo Fisher Scientific)
according to the manufacturer’s instructions. Purified RNA was
quantified with a Nanodrop Spectrophotometer (Thermo
Fisher Scientific), and 1 μg was retrotranscribed into cDNA
with the High-Capacity cDNA Reverse Transcription Kit
(Thermo Fisher Scientific). mRNA levels were analyzed by
real-time PCR using retrotranscribed cDNA, Fast SYBR
Master Mix (Thermo Fisher Scientific) and ABI Prism7900HT
sequence detection system (Thermo Fisher Scientific) at the
Genomics and Massive Sequencing Facility (CBMSO-UAM).
Primers used to amplify the human genes were acquired from
Millipore-Sigma (KiCqStart SYBR Green Primers) for ALDOA
(Gene ID 226, primer pair 1), ENO1 (Gene ID 2023, primer
pair 1), GPI (Gene ID 2821, primer pair 1), ATP5F1 (Gene ID
515, primer pair 1), MDH2 (Gene ID 4191, primer pair 1),
OAT (Gene ID 4942, primer pair 1), RPL3 (Gene ID 6122,
primer pair 1), RPL8 (Gene ID 6122, primer pair 1), RPL15
(Gene ID 6138, primer pair 1), RPS3 (Gene ID 6188, primer
pair 1), RPS11 (Gene ID 6205, primer pair 1), EIF4E (Gene
ID 1977, primer pair 1), EIF3E (Gene ID 3646, primer pair 1),
EIF3A (Gene ID 8661, primer pair 1), EIF3B (Gene ID 8662,
primer pair 1) and EIF3D (Gene ID 8664, primer pair 1).
Other primers used were: β-F1-ATPase (F 5′-CTTCA-
ATGGGTCCCACCATA-3′ and R 5′-CAGCAGATTT-
TGGCAGGTG-3′), α-F1-ATPase (F 5′-GATAGAGCCG-
CCTAGAACCA-3′ and R 5′-TACTCCGCAGGCGGT-
A C T T - 3 ′ ) , L D H A ( F 5 ′ -
TCTCTGTAGCAGATTTGGCAGA-3′ and R 5′-AAGAC-
ATCATCCTTTATTCCGTAAA-3′), GAPDH (F 5′-
AGCCACATCGCTCAGACAC-3′ and R 5′-GCCCA-
ATACGACCAAATCC-3′), and β-actin (F 5′-CCAAC-
CGCGAGAAGATGA and R 5′-CCAGAGGCGTACAGG-
GATAG).
Preparation of Crude Initiation Factors
8 × 106 cells were homogenized in 0.5 mL of 20 mM Tris-HCl,
pH 7.6, containing 200 mM sucrose, 100 mM NH4Cl, 5 mM
magnesium acetate, 0.1 mM EDTA, 1 mM dithiothreitol, and 1
mM phenylmethylsulfonyl fluoride. Cells were centrifuged at
27 000g for 30 min, and the resulting supernatant was
centrifuged at 100 000g for 150 min to obtain the microsomal
and postmicrosomal (S-100) fractions. Pelleted microsomes
were resuspended in homogenization buffer devoid of Mg2+,
extracted with 0.5 M KCl under continuous shaking for 90
min, and centrifuged at 100 000g for 180 min, to recover the
supernatant containing the fraction of crude initiation factors.
Statistical Analysis
Statistical analyses were performed using a two-tailed Student’s
t test. The results shown are mean ± SEM. A p < 0.05 was
considered statistically significant.
■ RESULTS
DMOG Reprograms Energy Metabolism and Enhances
Cellular Proliferation
HIF-1α stabilization is known to enhance aerobic glycolysis.42
We confirmed that the inhibition of prolyl-hydroxylases by
DMOG treatment significantly increased HIF-1α levels in the
human colorectal cancer cell line HCT116 (Figure 1A).
Consistent with the HIF-1α-mediated shift of energy
metabolism we observed a high reduction in mitochondrial
respiration (Figure 1B) and a concomitant increase in the flux
of aerobic glycolysis (Figure 1C). This metabolic phenotype
was accompanied by a reduction in the p-CDK1/CDK1 ratio
(Figure 1D) and an increased rate of cellular proliferation
(Figure 1E), indicating that cell cycle progression is favored in
DMOG-treated cells. Overall, the results suggest that DMOG
promotes metabolic reprogramming to facilitate cellular
proliferation and cell cycle progression highlighting the
relevance of the inhibition of prolyl-hydroxylases for metabolic
adaptation.43
Figure 1. DMOG promotes a glycolytic switch and induces cellular proliferation.HCT116 cells were treated with 1 mM DMOG for 24 h or left
untreated. (A) Western blot analysis of HIF-1α expression in two different preparations. GAPDH is shown as loading control. (B,C) Oxygen
consumption (B) and lactate production (C) rates. The results shown are means ± SEM (n = 6−10). (D) Western blot analysis of p-CDK1 and
CDK1. The histogram shows the p-CDK1/CDK1 ratio normalized to the mean value in untreated cells. The results are means ± SEM (n = 4). (E)
Cellular proliferation determined by the incorporation of EdU into DNA. *p < 0.05 when compared to nontreated by Student’s t test.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.9b00239
J. Proteome Res. 2019, 18, 3142−3155
3145
Metabolic Reprogramming Affects the Turnover of
Enzymes of Energy Metabolism
Inhibition of prolyl-hydroxylases significantly reduced the
initial rate of synthesis of the catalytic subunit of the
mitochondrial ATP synthase (β-F1-ATPase), as assessed by
the incorporation of 35S-methionine when compared to control
cells (Figure 2A). In contrast, the relative rate of synthesis of
the glycolytic glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) increased in the presence of DMOG (Figure 2A).
However, and despite the high differences in the initial rates of
synthesis triggered by DMOG reprogramming, we did not
observe significant changes in the expression levels of β-F1-
ATPase, GAPDH, the mitochondrial HSP60, and glycolytic
enolase (ENO1) between control and DMOG-treated cells
(Figure 2B).
Assessment of the half-life of β-F1-ATPase and GAPDH by
pulse-chase experiments in the presence and absence of
DMOG revealed an increase in the half-life of β-F1-ATPase in
DMOG treated cells when compared to controls (Figure 2C).
In contrast, DMOG promoted an increase in the turnover rate
of GAPDH when compared to untreated cells (Figure 2C).
Taken together, these results suggest that DMOG rewires
energy metabolism by regulating the synthesis and the
turnover rate of mitochondrial and glycolytic proteins while
maintaining the steady state levels of the proteins involved in
these processes.
A Dynamic SILAC Approach To Assess the Turnover of the
Proteome
A stable isotopic labeling amino acid (SILAC) study of the
proteome was carried out to have a more complete picture of
the relevance of protein turnover in metabolic reprogramming
(Figure 2D). HCT116 cells were incubated in heavy medium
for at least nine cell divisions, resulting in almost 100% of cells
labeled with heavy arginine and lysine (R10, K8). At time 0,
cells were switched to light medium (R0, K0), and incubated
with or without DMOG during the indicated times (Figure
2D). For the SILAC experiments, the time-points sampled
after changing the medium to the light one were at 0, 6, 12, 24,
and 48 h (Figure 2D). After cellular recovery the proteins were
digested with trypsin and the resulting peptides were analyzed
in LC−MS/MS (Figure 2D). Switching the cells to light
medium triggers the progressive replacement of heavy peptides
Figure 2. DMOG promotes opposite changes in the synthesis and turnover of proteins of energy metabolism.HCT116 cells were treated with 1
mM DMOG for 24 h or left untreated. (A) Determination of β-F1-ATPase and GAPDH synthesis rates by 35S-methionine incorporation. The
fluorograms reveal the immunoprecipitated proteins in three different preparations. p.i. nonspecific immunoglobulin. The histograms show the
means ± SEM (n = 6). *p < 0.05 when compared to nontreated cells. (B) Western blot analysis of β-F1-ATPase, HSP60, enolase 1 (ENO1), and
GAPDH in three different preparations. (C) Pulse-chase experiment: After 35S-methionine labeling, β-F1-ATPase and GAPDH were
immunoprecipitated at the indicated time-points for the determination of protein turnover. Two or three different preparations are shown. p.i.
nonspecific immunoglobulin. The plots show the first order rate kinetics of the decay of the proteins in CRL (red lines, circles) and DMOG-treated
(black lines, diamonds) cells. The t1/2 is indicated in brackets. Results are the mean ± SEM from six determinations. P < 0.001 analyzed by linear
correlation of the slopes. (D) The scheme of the SILAC workflow followed to measure the turnover of cellular proteins. (E) The scheme shows the
distribution of the 266 proteins studied by the effect of DMOG. Green, proteins with increased half-life; Red, proteins with decreased half-life;
Gray, unaffected proteins.
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by light ones (Supplemental Figure S1). The percentage of the
relative isotopic abundance (RIA) of heavy protein groups and
heavy proteins identified in untreated and DMOG-treated cells
over time fits a first-order kinetic (Supplemental Figure S1B).
Out of the ∼6000 peptide sequences monitored in the analysis,
only those appearing at all time-points and conditions were
selected for the study of the turnover of the proteome. The
turnover of 396 and 428 proteins for DMOG-treated and
untreated cells were obtained, respectively, resulting in the
study of the half-life of 266 proteins in common between the
two conditions (overlap of ∼67%). The diagram (Figure 2E)
shows that 136, 21, and 109 proteins increased, decreased or
are unaffected in their half-life by DMOG treatment,
respectively (Figure 2E and Supplemental Tables S1−S3).
To visualize the changes in protein turnover using the
SILAC approach and the Peaks 8.5 software, we have
exemplified the calculation of the half-lives of three subunits
of the ATP synthase (Figure 3) and of three enzymes of
glycolysis (Figure 4) following the time-dependent changes in
peak-intensities of all the H and L peptides obtained for each
protein (Supplemental Figure S2 and S3). The analysis
indicated that DMOG induced a retardation of heavy peptides
replacement for the three subunits of the mitochondrial ATP
synthase β-F1, α-F1, and b1-F(o), which means a decrease in
turnover and a significant increase in their respective half-lives
(Figure 3A−C). The same analysis was done for three enzymes
of the glycolytic pathway (GAPDH, ALDOA and GPI) (Figure
4A−C). In this case, DMOG caused a significant increase in
the decay of heavy peptides and thus an increase in the
turnover of the proteins, in other words, a significant reduction
in their half-lives (Figure 4A−C). Overall, these results
confirmed the opposite trend in the changes induced by
DMOG treatment in the turnover of β-F1-ATPase and
GAPDH assessed by conventional 35S-Met labeling.
The Inhibition of Prolyl Hydroxylases Impacts on the
Turnover of Proteins Involved in Energy Metabolism
The GeneCodis web tool against Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways was used to recognize the
pathways that are most strongly influenced by DMOG
treatment.38−40 The analysis revealed that proteins involved
in energy metabolism and in the translational machinery were
the ones preferentially represented (Figure 5A). In fact, of the
38 mitochondrial proteins included in the study, ∼76% of
them revealed a significant increase in their half-lives as a result
of DMOG treatment (Figure 5B). The rest of mitochondrial
proteins detected revealed no major changes in their turnover.
Figure 3. Half-life calculation for three subunits of the mitochondrial ATP synthase in response to DMOG treatment. The decay of heavy-peptides
(blue diamonds) and concurrent appearance of light-peptides (orange squares) at the indicated time-points of the chase are shown for β-F1-
ATPase (A), α-F1-ATPase (B), and Fo-ATPase subunit B1 (C) for DMOG-treated and nontreated cells. The half-life (t1/2) of each protein was
calculated as the time elapsed when their peptides have the same relative isotopic abundance (RIA = 0.5). The results shown are means ± SEM of
the half-lives of the different peptides studied for each subunit. *p < 0.05, **p < 0.01 and ***p < 0.001, when compared to nontreated by Student’s
t test. ATP5B, ATP5A and ATP5F1, correspond to β-subunit, α-subunit and subunit b1 of the Fo complex of the ATP synthase, respectively.
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Interestingly, the mitochondrial NAD+-dependent malic
enzyme showed a sharp reduction in its half-life (Figure 5B).
In contrast to these findings, ∼67% of the glycolytic proteins
studied showed a significant reduction in their half-lives upon
DMOG treatment (Figure 5C). Overall, the results indicate
that inhibition of prolyl hydroxylases have significant opposite
effects in the regulation of the turnover of proteins involved in
energy metabolism.
Determination of DMOG-induced changes in mRNA
availability in some of the enzymes of energy metabolism
revealed the lack of changes for the mitochondrial
(Supplemental Figure S4A) and some of the glycolytic
(Supplemental Figure S4B) proteins studied. Interestingly,
and in the particular case of the cluster of glycolytic enzymes,
we observed a significant inverse correlation between DMOG-
induced changes in mRNA availability and the half-lives of the
proteins (Supplemental Figure S4C).
The Inhibition of Prolyl-Hydroxylases Promotes an Overall
Stabilization of Proteins Involved in Translation
The turnover of ribosomal proteins and of translation initiation
factors is of particular importance because translational control
is critical for adaptation of the cells during development,
differentiation, aging, and disease.44 Of the ribosomal proteins
detected, ∼94% of them showed a significant increase in their
half-lives upon DMOG treatment when compared to control
cells (Figure 6A). Only 2 of the 33 ribosomal proteins
detected, showed significant reduction in their half-lives in
DMOG-treated cells (Figure 6A). Interestingly, purified
ribosomal proteins from untreated and DMOG-treated cells
(Supplemental Figure.S5A) and blotting against the acidic P0,
P1/P2 ribosomal proteins (Supplemental Figure S5B)
indicated that their cellular abundance is not affected by
DMOG treatment. This point was also confirmed by LC-ESI-
MS analysis that identified 765 and 812 peptides of 92% of the
ribosomal proteins in control and DMOG treated cells,
respectively (Supplemental Figure S5C).
Of the initiation/elongation factors detected, 70% of them
had a significant increase in their half-lives upon DMOG-
treatment (Figure 6B). Interestingly, whereas proteins of
energy metabolism and of the ribosome do not show relevant
changes in expression after 24−48 h treatment with DMOG
(Figure 2B and Supplemental Figure S5), the expression of
eukaryotic translation initiation factors eIF3A, eIF3D, eIF3E,
and eIF4E was significantly reduced in DMOG-treated cells
(Figure 6C).
Figure 4. Half-life calculation for three glycolytic enzymes in response to DMOG treatment. The decay of heavy-peptides (blue diamonds) and
concurrent appearance of light-peptides (orange squares) at the indicated time-points of the chase are shown for GAPDH (A), ALDOA (B), and
GPI (C) for DMOG-treated and nontreated cells. The half-life (t1/2) of each protein was calculated as the time elapsed when their peptides have
the same relative isotopic abundance (RIA = 0.5). The results shown are means ± SEM of the half-lives of the different peptides studied for each
protein. ***p < 0.001 when compared to nontreated by Student’s t test. GAPDH, ALDOA, and GPI correspond to glyceraldehyde-3-phosphate
dehydrogenase, fructose-bisphosphate aldolase A, and glucose-6-phosphate isomerase, respectively.
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Determination of DMOG-induced changes in cellular
mRNA availability of proteins of the translation machinery
indicated the lack of relevant differences for mRNAs encoding
ribosomal proteins (Supplemental Figure 6A). In contrast, and
despite the availability of mRNAs of translation initiation
factors showed an increase upon DMOG treatment (Supple-
mental Figure 6B), their steady-state protein content was
significantly decreased (Figure 6C), albeit their turnover was
slowed-down (Figure 6B).
DMOG Inhibits mTORC1 Signaling and Cap-Dependent
Translation
mTORC1/S6K signaling pathway positively controls protein
translation, ribosomal biogenesis and protein degradation.45,46
The metabolic reprogramming triggered by DMOG signifi-
cantly affected the phosphorylation of mTORC1 and of its
downstream targets S6K, S6, and 4EBP1 (Figure 7A)
suggesting the inhibition of the mTORC1 signaling pathway
and its contribution in the repression of protein synthesis of
mitochondrial, ribosomal and translation factors during
metabolic reprogramming (Figure 7B). In contrast, the
increased synthesis of glycolytic proteins in response to
DMOG treatment was mTOR independent (Figure 7B).
The mitochondrial generation of ROS (mtROS) is a
relevant signal to coordinate nuclear programs aimed at
adapting cellular responses to changing cues47−50 and mtROS
are known to trigger the inhibition of PHD and stabilized HIF-
1α.51−53 Analysis of the turnover of the different subcellular
proteomes in the presence of MitoQ, a mitochondrial targeted
ROS scavenger, indicated a significant 2-fold increase in the
half-life of all the proteomes investigated, both in the absence
or presence of DMOG (Supplemental Figure S7), suggesting
the importance of protein oxidation in defining overall protein
turnover. The effect of MitoQ however, was less relevant in the
turnover of glycolytic proteins, especially under DMOG
treatment (Supplemental Figure S7). In the MitoQ and
MitoQ+DMOG experiments, we obtained the turnover for 192
and 371 proteins, respectively. The overlaps with the proteins
found in common in the DMOG/untreated experiment were
Figure 5. Half-life of proteins of translation and energy metabolism are major targets of DMOG treatment. (A) GeneCodis analysis against KEGG
pathways. Green and red bars respectively represent the proteins with decreased and increased turnover in DMOG treated cells when compared to
nontreated. Hypergeometric values (Hyp) of each KEGG pathway are also indicated. OXPHOS, oxidative phosphorylation; TCA, tricarboxylic acid
cycle; KEGG, Kyoto Encyclopedia of Genes and Genomes. (B,C) The results illustrate the half-life (h) in the absence (CRL) or presence of
DMOG and percentage change in the half-life of the indicated mitochondrial (B) and of glycolytic (C) protein when compared to nontreated cells
as determined by the Peaks 8.5 software. The histograms show the means ± SEM of the half-lives of the total number of mitochondrial (B) and
glycolytic (C) proteins included in the study. *p < 0.05 and ***p < 0.001, when compared to nontreated by Student’s t test.
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160 and 161 proteins, respectively. Supplemental Tables S4−
S7 only list the glycolytic, mitochondrial, ribosomal, and
translation factors in common in all the experiments.
Interestingly, the turnover of the different cellular proteomes
investigated was also similarly upregulated when protein
degradation was blocked with the broad spectrum protease
inhibitor leupeptin that inhibits cysteine, serine and threonine
peptidases (Supplemental Figure S7). In the leupeptin
experiment, we obtained the turnover for 386 proteins and
the overlap with the proteins found in common in the
DMOG/untreated experiment was 148 proteins (Supplemen-
tal Tables S4−S7). The inhibition of protein degradation by
leupeptin most likely reflects the turnover of the majority of
the cellular proteins degraded by lysosomes, including those
degraded by autophagy, and the ones localized in mitochondria
also degraded by calpains and other serine proteases, further
suggesting a prominent role for reactive oxygen species in
regulating overall protein turnover.
■ DISCUSSION
Herein, we have investigated the role of protein turnover for
cellular adaptation during metabolic reprogramming to an
enhanced aerobic glycolysis using DMOG, an inhibitor of
prolyl-hydroxylases. In agreement with previous findings in
cardiomyocytes,12 cancer cells14 and bone marrow-derived
angiogenic cells,5 DMOG induced HIF-1α expression,
inhibited mitochondrial respiration, promoted aerobic glycol-
ysis and stimulated cellular proliferation of colon cancer cells.6
These findings are in agreement with a previous study that
showed that proliferation of colon cancer cells requires the
selection of cells with a highly glycolytic phenotype.26
Interestingly, DMOG inhibited CDK1 phosphorylation
which is sufficient to drive cell cycle progression.54 Moreover,
CDK1 has been shown to contribute to the stability and
transcriptional activity of HIF-1α by blocking its lysosomal
degradation.55
As an exploratory attempt to investigate the potential
implication of protein turnover in metabolic reprogramming,
we first studied by a conventional approach the synthesis and
Figure 6. DMOG increased the half-life of ribosomal proteins and translation factors. (A,B) The results illustrate the half-life (h) in the absence
(CRL) or presence of DMOG and percentage change in the half-life of the indicated ribosomal proteins (A) and translation factors (B) when
compared to nontreated cells as determined by the Peaks 8.5 software. The histograms show the means ± SEM of the half-lives of the total number
of ribosomal proteins (A) and translation factors (B) included in the study. **p < 0.01 and ***p < 0.001, when compared to nontreated by
Student’s t test. (C) Western blot analysis of the expression of the eukaryotic translation initiation factors eIF3A, eIF3D, eIF3E and eIF4E in
HCT116 cells treated (+) with 1 mM DMOG for 24h or left untreated (−). GAPDH and β-actin are shown as loading controls. The histograms
show the quantification of the bands (a.u.) normalized to the mean value in untreated cells. The results shown are means ± SEM (n = 3). **p <
0.01, when compared to nontreated by Student’s t test.
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turnover of the mitochondrial β-F1-ATPase protein of
OXPHOS and GAPDH of glycolysis. These proteins
respectively represent biomarkers that estimate the relative
changes of OXPHOS and glycolysis during metabolic
reprogramming as defined in the “bioenergetic signature”.56−59
Consistent with the onset of metabolic reprogramming,
DMOG triggered the inhibition of the synthesis of β-F1-
ATPase and the concurrent enhanced synthesis of GAPDH.
Similar findings on the synthesis of both proteins have been
obtained when reprogramming was induced by oligomycin
treatment.28 Moreover, these changes were paralleled by an
increase in the stability of the mitochondrial β-F1-ATPase,
whereas the turnover of the glycolytic GAPDH was
significantly accelerated. Interestingly, and despite the rapid
and opposite changes in the synthesis and turnover of the two
enzymes of energy metabolism, the steady state expression of
the two proteins was not affected after 48 h of DMOG
treatment. These findings contrasted with the sharp reduction
of the steady-state expression of mitochondrial proteins in
response to oligomycin treatment,28 suggesting that changes in
the “bioenergetic signature” of the cell requires a sustained and
long-term pressure on the metabolic proteome for reprogram-
ming.
On the basis of the above exploratory results we investigated
the turnover of the cellular proteome by a high-throughput
dynamic SILAC approach36,60,61 during DMOG-induced
reprogramming. Of note, most of the proteins that showed
significant changes in turnover were stabilized by DMOG
treatment in differentiated cardiomyocytes,62 suggesting a
relevant role for prolyl-hydroxylases in proteostasis. In
agreement with these authors, we observed that 51% of the
proteins identified in our study become stabilized by DMOG
treatment. Proteins in common between both studies are
chaperones (PDIA3, PDIA4, CALR, HSPB1), nucleic acid
binding proteins (SFPQ, XRCC5, PCBP1) and proteins with
enzymatic activity (GANAB, LDHB). On the contrary,
proteins involved in glycolysis (ALDOA and GAPDH),
endolysosomal trafficking (RAB7A), assembly of ribonucleo-
proteins (STRAP), cell adhesion (TES) and cell cycle
regulation (CLIC1) showed an increase in their turnover in
colon cancer cells whereas were stabilized in differentiated
cardiomyocytes.62 These differences might stem from the
different metabolic requirements that exist between a differ-
Figure 7. DMOG inhibits the mTORC1 signaling pathway. HCT116 cells were treated with 1 mM DMOG for 24 h or left untreated. (A) Western
blot analysis of the expression of p-mTORC1, mTORC1, p-p70S6K, p70S6K, p-S6, S6, p-4EBP1, and 4EBP1 in three different preparations. β-actin
is shown as loading control. The histograms show the quantification of the bands (a.u.) normalized to the mean value in untreated cells. The results
shown are means ± SEM (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001, when compared to nontreated by Student’s t test. (B) The scheme
summarizes the effects of DMOG-mediated reprogramming in the turnover of glycolytic, mitochondrial and ribosomal proteins and translation
factors. PHD, prolyl-hydroxylases; HIF-1α, Hypoxia inducible factor 1α; mTORC1, mammalian target of rapamycin complex 1; S6K1, S6 kinase 1;
4EBP1, eIF4E binding protein 1.
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entiated cardiomyocyte and a proliferative cancer cell. Of note,
only in ∼3% of the proteins that showed a relevant change in
protein turnover as a result of DMOG treatment showed
nonhydroxylated proline residues in their tryptic peptides.
Following the stringent criteria in the selection of the
proteins included in the study, the major subcellular proteomes
affected by stabilization were those involved in protein
synthesis and mitochondrial OXPHOS and metabolism.
Specifically, and regarding mitochondria, key OXPHOS
proteins that showed significantly reduced turnover rates in
cells treated with DMOG included components of the
respiratory chain (UQCRC2, CYCS), ATP synthase
(ATP5F1, ATP5B, ATP5A), phosphate and adenine nucleo-
tide transporters (SLC25A3, SLC25A5), metabolic enzymes
(GOT2, MDH2, SHMT2, AK2) and molecular chaperones
(HSPA9, HSPE1, HSPD1). In contrast, relevant proteins that
showed a significant increase in its turnover upon DMOG
treatment were enzymes of the glycolytic pathway (GPI,
ALDOA, ENO1, GAPDH), confirming and further emphasiz-
ing the opposite and rapid regulation of the turnover of
mitochondrial and glycolytic proteins during metabolic
reprogramming.
The regulation of the expression of OXPHOS genes is
exerted at post-transcriptional levels during development,
differentiation and in oncogenesis.63−65 Consistently, the
changes in protein turnover triggered by DMOG on
mitochondrial proteins are not paralleled by changes in
mRNA abundance. In contrast, we found that the half-life of
the cluster of glycolytic enzymes studied inversely correlates
with the cellular availability of their mRNAs in response to
DMOG, suggesting a link between the rate of protein turnover
and the transcriptional response. Overall, and in agreement
with previous findings by others, there is partial correlation
between mRNA levels and protein expression and turnover.
Remarkably, the inhibition of mitochondrial respiration and
the activation of aerobic glycolysis respectively correlated with
the stabilization of the turnover of mitochondrial proteins and
the activation of the turnover of glycolytic enzymes, supporting
that the metabolic flux through a given pathway correlates with
changes in the turnover of the proteins involved. These results
suggest the idea that the renewal of proteins is enhanced when
the metabolic pathway is activated. In other words, the
metabolic activity determines enzymes’ half-life.
Although our results indicate a rather general DMOG-
mediated shutdown of protein synthesis and concurrent
protein stabilization of different cellular compartments, the
inhibition is selective because the translation and turnover of
glycolytic proteins is enhanced. mTORC1 is a master regulator
of protein synthesis whose activation positively controls cap-
dependent translation, ribosome biogenesis18,66 and the
maintenance of the bioenergetic function of mitochon-
dria.28,67,68 Consistent with our findings, DMOG treatment
significantly repressed the mTORC1 pathway as revealed by its
diminished phosphorylation and that of its downstream targets
p70S6K and 4EBP1, which control the biosynthesis of
ribosomes and the 5′-cap dependent translation of nuclear
encoded mitochondrial mRNAs (Figure 7B).69 Overall, these
results emphasize the relevance of the inhibition of mTORC1
pathway in controlling protein synthesis and turnover for
metabolic adaptation to an enhanced glycolytic phenotype.
Recent findings have stressed the relevance of a diminished
hypusination of the translation initiation factor eIF5A in
metabolic reprogramming to an enhanced glycolysis, to confer
resistance to anoxic cell death by inhibiting the synthesis of
nuclear encoded mitochondrial proteins.70 In this regard, we
cannot ruled out the participation of DMOG elicited HIF-1α-
independent mechanisms71−73 that might affect eIF5A
hypusination in silencing the synthesis of mitochondrial
proteins during reprogramming.
On the contrary, the synthesis and turnover of glycolytic
enzymes are significantly stimulated upon DMOG treatment
strongly emphasizing the differential regulation of the two
main pathways of energy metabolism during metabolic
reprogramming. Indeed, we found that whereas the synthesis
of mitochondrial proteins is largely mTORC1-dependent
through cap-dependent translation the synthesis of glycolytic
enzymes is not. It is tempting to suggest that the synthesis of
glycolytic enzymes shares signaling pathways and mechanisms
with proteins involved in cellular adaptation to stressful
conditions.74,75
Consistent with the role of serine-proteases in controlling
protein degradation76 we observed that incubation of the cells
with leupeptin triggered a ∼2 fold increase in the stability of all
the subcellular proteomes investigated. Mitochondria are
primary signaling hubs of the cell,50,77 and mtROS represent
a relevant signaling molecule that emanates from its activity
affecting both cell fate and behavior.48−50 Hence, we
interrogated whether the mtROS produced in response to
the inhibition of prolyl hydroxylases could be involved in
regulating protein turnover. Remarkably, we found that in
control non-DMOG treated cells, MitoQ already stabilized all
the subcellular proteomes of the cells to the same level as
leupeptin irrespective of DMOG treatment. Since MitoQ is
unlikely to affect the activity of serine proteases, our results
suggest that the basal oxidation of cellular proteins is a main
determinant controlling protein turnover, being the mtROS
produced in response to DMOG treatment of marginal
relevance in this situation.
The contribution of the different protein degradation
pathways that are activated/repressed during reprogramming
deserve future investigations because of the prominent role
played by proteostasis in aging and age-related diseases.18,44,77
In this regard, and in agreement with our results of an
enhanced turnover of mitochondrial proteins when OXPHOS
is activated, it has been described that the stimulation of
OXPHOS enhances Rheb-dependent mitophagy,78,79 a mech-
anism to promote renewal of the organelles to ensure optimal
mitochondrial energy production. Alternatively, the PINK1-
Parkin pathway that mediates the selective turnover of proteins
of the mitochondrial respiratory chain80 could also be involved
in promoting the selective degradation of these proteins upon
activation of OXPHOS. Since autophagy is enhanced in colon
cancer cells that rewire its metabolism to an increased
glycolysis,28 it is quite likely the implication of this pathway
in facilitating the renewal of specific proteins during
reprogramming.
To summarize, our findings strongly support that switching
energy metabolism from mitochondrial OXPHOS to aerobic
glycolysis requires a profound and opposite change in the
regulation of the turnover of glycolytic and mitochondrial
proteins. Inhibition of the mTORC1 signaling pathway gears
the partial silencing of the synthesis and stabilization of
mitochondrial and ribosomal proteins during reprogramming.
Finally, the basal production of mtROS seem to play a
fundamental role in defining the overall turnover of the cellular
proteome.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.9b00239
J. Proteome Res. 2019, 18, 3142−3155
3152
■ CONCLUSIONS
The turnover of different subcellular proteomes is significantly
altered during metabolic reprogramming to an enhanced
DMOG-mediated glycolytic phenotype. Specifically, inhibition
of the mTOR pathway seems to gear the stabilization of the
majority of mitochondrial and ribosomal proteins and
translation initiation factors. In contrast, the synthesis and
turnover of glycolytic enzymes is significantly accelerated
during reprogramming by an mTOR-independent mechanism.
The overall turnover of the proteome is profoundly stabilized
by inhibitors of serine-proteases and by a mitochondrial
targeted antioxidant.
Information of Proteomic experiments
The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE partner
repository with the data set identifier PXD013482 and
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